What Dilatol Treats: Main Uses and Benefits

Dilatol is commonly used for the long-term management of essential hypertension and is relevant for easing symptoms related to chronic stable angina pectoris. This medication provides support that helps ease the overall symptom burden associated with cardiovascular risk. The therapeutic focus is on addressing symptoms related to systemic imbalance (high blood pressure) and symptoms related to physical discomfort (angina).

In clinical settings, Dilatol is applied in addressing these conditions either alone or as part of a combination therapy with other agents. This supports patients during episodes of heightened discomfort and assists with maintaining functional stability in their daily routine.

The medication is relevant for easing conditions presenting with symptoms of high blood pressure and chronic angina.

“This approach contributes to easing the overall symptom load related to chronic cardiovascular stress.”

---

Quick Fact: Relief for Elevated Arterial Pressure

Regulatory References

1. NIH MedlinePlus overview

Official Eligibility and Contraindications for Dilatol (Phenytoin)

The official regulatory profile strictly defines who may use Dilatol based on medical status, age, and hypersensitivity. Eligibility is classified into three categories: Contraindicated, Restricted, and Conditional Use.

Category	Key Populations or Conditions
Contraindicated	Patients with known hypersensitivity to phenytoin or other hydantoins. Also contraindicated in patients with specific cardiac conduction issues, including sinus bradycardia and certain A-V blocks (second/third-degree). Use is prohibited with a history of acute hepatotoxicity due to phenytoin.
Restricted Use	Pregnancy: Prenatal exposure is associated with increased risks for congenital malformations. Use requires careful monitoring and risk assessment. Lactation: The drug is secreted into human milk; caution is advised.
Conditional Use	Hepatic or Renal Impairment: Patients with liver or kidney disease, or hypoalbuminemia, may have altered drug clearance. Eligibility requires close monitoring of unbound phenytoin concentrations and possible dose adjustment.

Age-Related Eligibility: While established for use in adults and children (over six years), geriatric patients and neonates require special consideration due to slower clearance and altered pharmacokinetics, necessitating lower starting doses and vigilant monitoring.

Dilatol's eligibility structure ensures that individuals with pre-existing conditions that significantly alter drug metabolism or pose an absolute cardiac risk are excluded or receive tightly controlled therapy, as mandated by regulatory bodies.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Dilatol primarily through its metabolic pathway and the risk of additive pharmacological effects. The most clinically significant interactions involve medicines that are strong inhibitors or inducers of specific CYP enzymes responsible for Dilatol's metabolism. Co-administration with enzyme inhibitors can dangerously increase Dilatol's concentration, while inducers can decrease its effectiveness, both requiring specialized patient monitoring and possible therapy changes.

A key restriction noted in regulatory documents is the contraindication of co-administration with specific drugs, such as Delavirdine, where the pharmacokinetic interaction is explicitly linked to a risk of therapeutic failure and possible viral resistance. Other interacting medicinal products include Valproic acid, Phenobarbital, and certain Calcium Channel Blockers (e.g., Nifedipine, Verapamil), where careful review of clinical effects is necessary.

Interaction-Related Constraints

The official profile lists constraints tied to co-ingestion: concurrent use with alcohol must be avoided due to the potential for altered blood levels. Furthermore, regulatory information advises that other oral medications, particularly Antacids, may require timing separation (e.g., two hours before or after) to prevent altered gastrointestinal absorption of Dilatol, which impacts its overall effectiveness. Slow metabolizers are also identified as a population requiring heightened awareness for the risk of elevated serum levels of the drug.

Selective Blockade of Vascular Calcium Channels

The pharmacological action of Dilatol (Isradipine) is defined by its selective interruption of the calcium signaling pathway within the peripheral vasculature, resulting in systemic changes to blood flow dynamics. The core mechanism is the high-affinity antagonism of L-type Voltage-Gated Calcium Channels (CaV1.2) found primarily on Vascular Smooth Muscle Cells (VSMCs). By stabilizing the inactive state of these channels, the drug blocks the necessary influx of Ca^2+ ions, which are the essential molecular mediators that trigger arterial muscle contraction.

---

Modulation of Arteriolar Smooth Muscle Tone

The consequence of reduced intracellular calcium is the interruption of the excitation-contraction coupling pathway, resulting in the relaxation and widening (vasodilation) of the peripheral arteries. This mechanism is intrinsically vasoselective, meaning it focuses its disruptive action on the blood vessels, ensuring that the primary hemodynamic effect is vasodilation with minimal direct impact on the heart’s natural rate or strength.

---

Systemic Reduction of Afterload

This widespread relaxation of the arteries drastically decreases the Peripheral Vascular Resistance (PVR) throughout the circulatory system. This systemic change directly reduces the mechanical force, known as cardiac afterload, against which the heart must pump, resulting in a reduction of the mechanical workload on the left ventricle.

Official Administration Guidelines for Dilatol

Dilatol is available for administration by Oral ingestion (tablets and extended-release capsules) and Intravenous Infusion (injection). The official instructions for use dictate a specific starting dose, frequency, and method of preparation depending on the form prescribed.

Dosage Form & Route	Standard Frequency	Administration Note
Immediate-Release Tablet (Oral)	Twice daily (BID) or Three times daily (TID)	May be taken with or without food.
Extended-Release Capsule (Oral)	Once daily (QD)	Must be swallowed whole; do not crush, split, or chew.
Solution for Injection (IV)	Continuous Infusion	Must be diluted prior to administration and administered slowly, typically over a minimum of 30 minutes.

Dosing and Population Rules

Adult Dosing: The common starting dose for oral therapy is 10 mg taken twice per day, with the dosage adjusted based on individual response, up to a maximum total daily dose defined in the product labeling. For intravenous use, a loading dose is followed by a continuous infusion. Missed Doses should be taken as soon as remembered unless it is near the time for the next scheduled dose, in which case the missed dose should be skipped; do not take two doses to make up the difference.

Special Populations: The official regulatory instructions require dose reduction for individuals with impaired kidney function, such as a CrCl < 30 mL/ min, where the maximum daily dose must be reduced. Pediatric dosing is based on Body Surface Area ( BSA).

Research Evidence / Overview of Studies for Dilatol (Isradipine)

The research into Dilatol for high blood pressure includes numerous Randomized Controlled Trials (RCTs). These studies randomly assigned participants to receive Dilatol, a placebo, or an active comparator agent that research also examined for high blood pressure. Researchers monitored and measured specific outcomes related to high blood pressure, particularly focusing on changes in blood pressure readings, such as systolic and diastolic pressure, typically measured at a defined time point in the dosing interval. Studies describe patterns observed in blood pressure measurements, including changes in both key pressure numbers recorded across various patient groups. Furthermore, studies monitored changes in surrogate outcomes, such as measurements related to left ventricular hypertrophy (LVH).

Research exploring Dilatol for chronic stable angina pectoris, a condition marked by functional limitations and symptoms, included short-term, randomized, placebo-controlled trials. These studies focused on measuring symptom-related changes. Researchers monitored and tracked patient-reported outcomes describing perceived discomfort, such as the number and severity of angina episodes, and the consumption of relief medication. Studies reported measured changes in physical function, such as those related to exercise duration or time to symptom onset on testing. These reported outcomes were primarily collected during acute and short-term assessment periods.

---

Long-Term Studies and Follow-up Duration

The initial, comprehensive studies for Dilatol were conducted over short-term follow-up durations, typically lasting a few weeks or months. For high blood pressure, some individual trials were extended for intermediate-term monitoring, lasting up to a year. Long-term effects are not fully established by individual Dilatol-specific studies extending over many years. To gain insight into sustained outcomes, scientific reviewers often rely on systematic reviews and meta-analyses, which combine data from many individual trials to look for broader patterns related to long-term health outcomes. Evidence from long-duration individual trials is limited.

---

Research Gaps and Areas of Uncertainty

Research highlights that the follow-up durations were limited in many of the initial randomized trials, especially those concerning angina. This means that the research provides insight into short-term changes but less information about the consistency of findings or the pattern of effects after several years of use. While the evidence base for blood pressure control is substantial, the comparative evidence is lacking for certain pairings or strategies, and sample sizes were limited in some of the angina studies. Data for certain groups, such as pediatric patients or subgroups also managing other health conditions, remain insufficient.

Key Studies & References

1. Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis (Review of 32 published and 33 unpublished studies, 9,903 participants)
2. Duration of Effects of Isradipine During Twice Daily Therapy in Angina Pectoris (Placebo-controlled RCT focusing on exercise time and duration of effect)
3. The Safety of Calcium Antagonists: An Update (Review covering long-term risk and comparison within the CCB class, relevant to long-term section)

Common questions about Dilatol (FAQ)

Q: How long does it usually take for Dilatol to start having an effect?

According to official product information, a noticeable decrease in blood pressure may begin within two to three hours after taking a single oral dose. However, the official documentation states that the maximum therapeutic response during long-term daily treatment may not be apparent for two to four weeks of continuous administration.

Q: Is Dilatol known to cause weight gain or loss?

Changes in weight (gain or loss) are not listed among the common or frequently reported adverse reactions in official regulatory documents for Dilatol.

Q: Is it common for Dilatol to cause changes in mood?

Changes in mood or psychiatric disturbances are not listed among the commonly or frequently reported adverse reactions in the official prescribing information for Dilatol.

Q: How long does the effect of one Dilatol dose typically last?

Official regulatory information on Dilatol's pharmacokinetics indicates that the blood pressure-lowering effect for a single dose is often maintained for more than 12 hours. This pattern is related to the drug’s terminal half-life, which is approximately eight hours.

Q: Is it true that Dilatol can affect blood sugar levels?

Official prescribing information on adverse reactions does not list changes in blood sugar levels (glucose) as a common or frequently reported effect associated with Dilatol.

Q: Is a metallic taste in the mouth sometimes reported with Dilatol?

Disturbances of taste, including a metallic taste, are not listed among the common or frequently reported adverse reactions found in official regulatory documents for Dilatol.

Q: Can taking Dilatol cause increased sensitivity to the sun?

Increased sensitivity to the sun (photosensitivity) is not listed as a common or frequently reported adverse reaction in the official prescribing information for Dilatol.

Q: Is Dilatol available over-the-counter in any country?

Official regulatory sources, such as the U.S. Food and Drug Administration (FDA), classify Dilatol (Isradipine) as a Human Prescription Drug. This indicates that the medicine is only available with a valid prescription.

Q: Can I take Dilatol with vitamins or supplements?

Official drug information notes that patients should inform their health care professional about all products they are taking. This includes any vitamins, supplements, or herbal remedies, as interactions between these substances and Dilatol may occur.

Q: Does Dilatol affect fertility?

The effects of Dilatol on human fertility are not fully established in the regulatory documentation. However, there are no specific warnings related to human fertility consistently listed in the official Warnings and Precautions section.

Q: Are there any known interactions between Dilatol and herbal remedies?

Official regulatory information notes the need to inform a health care professional about all products consumed, including herbal remedies or supplements. This is due to the potential for interactions between these substances and Dilatol.

Q: Does Dilatol have a 'black box warning' in the US?

Official prescribing information released by the U.S. Food and Drug Administration (FDA) does not contain a Boxed Warning for Dilatol.

Q: Does Dilatol have a high potential for misuse or dependency?

Dilatol (Isradipine) is not designated as a controlled substance and is not listed on the schedule of controlled substances maintained by the U.S. Drug Enforcement Administration (DEA). This suggests official sources do not classify it as having a high potential for misuse or dependency.

Q: Is Dilatol commonly prescribed alongside other medications for the same condition?

Official dosing guidelines describe Dilatol as a treatment that may be used alone (monotherapy) or as an addition to existing therapy with other agents, such as thiazide-type diuretics, for managing high blood pressure.

Q: Are there specific instructions for what to do if an allergic reaction to Dilatol occurs?

Hypersensitivity to Dilatol is listed as a contraindication for use in official drug information. The occurrence of symptoms suggesting an allergic reaction necessitates immediate professional medical intervention.

Q: Can Dilatol be taken if someone is scheduled for surgery?

Official interaction information notes a risk of severe low blood pressure (hypotension) reported during certain types of anesthesia, such as Fentanyl anesthesia, when used alongside a calcium channel blocker. The regulatory context emphasizes the need for healthcare providers to be aware of all medications prior to any surgical procedure.

Q: Are there specific official guidelines about Dilatol and mental health conditions?

Mental health conditions are not listed as a contraindication for using Dilatol in official labeling. Furthermore, the Adverse Reactions section does not commonly report severe psychiatric disorders.

Q: What is the official classification of Dilatol (e.g., Schedule 4, Prescription Only)?

Dilatol (Isradipine) is officially classified as a Human Prescription Drug in the U.S. and is not categorized as a controlled substance on the Drug Enforcement Administration (DEA) schedule.

Official Storage Requirements

Dilatol (Isradipine) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The product must be protected from light and moisture, and the container must be kept tightly closed in its original packaging. Regulatory labeling strictly instructs that the medication must not be frozen.

Handling and Disposal

The medicine must always be stored out of the reach of children. For unused or expired product, the official requirement is to dispose of the medication according to local regulations for pharmaceutical waste. Unless otherwise instructed by a healthcare provider, the product should not be flushed down a toilet or poured into a drain.